1. Home
  2. BMEA vs EXFY Comparison

BMEA vs EXFY Comparison

Compare BMEA & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • EXFY
  • Stock Information
  • Founded
  • BMEA 2017
  • EXFY 2008
  • Country
  • BMEA United States
  • EXFY United States
  • Employees
  • BMEA N/A
  • EXFY N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • EXFY Computer Software: Prepackaged Software
  • Sector
  • BMEA Health Care
  • EXFY Technology
  • Exchange
  • BMEA Nasdaq
  • EXFY Nasdaq
  • Market Cap
  • BMEA 275.6M
  • EXFY 241.7M
  • IPO Year
  • BMEA 2021
  • EXFY 2021
  • Fundamental
  • Price
  • BMEA $6.38
  • EXFY $3.32
  • Analyst Decision
  • BMEA Buy
  • EXFY Buy
  • Analyst Count
  • BMEA 13
  • EXFY 4
  • Target Price
  • BMEA $37.25
  • EXFY $2.83
  • AVG Volume (30 Days)
  • BMEA 814.9K
  • EXFY 786.0K
  • Earning Date
  • BMEA 10-29-2024
  • EXFY 11-07-2024
  • Dividend Yield
  • BMEA N/A
  • EXFY N/A
  • EPS Growth
  • BMEA N/A
  • EXFY N/A
  • EPS
  • BMEA N/A
  • EXFY N/A
  • Revenue
  • BMEA N/A
  • EXFY $137,440,000.00
  • Revenue This Year
  • BMEA N/A
  • EXFY N/A
  • Revenue Next Year
  • BMEA N/A
  • EXFY $7.39
  • P/E Ratio
  • BMEA N/A
  • EXFY N/A
  • Revenue Growth
  • BMEA N/A
  • EXFY N/A
  • 52 Week Low
  • BMEA $3.61
  • EXFY $1.24
  • 52 Week High
  • BMEA $22.74
  • EXFY $3.34
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 24.23
  • EXFY 80.91
  • Support Level
  • BMEA $6.04
  • EXFY $2.63
  • Resistance Level
  • BMEA $9.34
  • EXFY $2.97
  • Average True Range (ATR)
  • BMEA 0.54
  • EXFY 0.22
  • MACD
  • BMEA -0.26
  • EXFY 0.10
  • Stochastic Oscillator
  • BMEA 10.30
  • EXFY 99.01

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.

Share on Social Networks: